Ista Pharmaceuticals, Inc. (ISTA) Cash Flow Statement

Click line-items for a historical chart and %

Net (loss) income	-17.81M
Stock-based compensation costs	1.53M
Amortization of deferred financing costs	188K
Amortization of discounts on Facility Agreement	500K
Change in value of warrants related to Facility Agreement	13.01M
Change in value of derivative related to Facility Agreement	1.75M
Depreciation and amortization	604K
Accounts receivable, net	11.04M
Inventory, net	-550K
Other current assets	-385K
Accounts payable	2.83M
Accrued compensation and related expenses	-754K
Allowance for rebates and chargebacks	3.16M
Allowance for product returns	698K
Royalties payable	-19.62M
Other accrued expenses	4.12M
Deferred rent and other long term liabilities	-66K
Net cash (used in) provided by operating activities	-9.01M
Purchases of equipment	-496K
Deposits and other assets	0
Net cash used in investing activities	-496K
Proceeds from exercise of warrants
Proceeds from exercise of stock options	643K
Proceeds from issuance of common stock for ESPP
Payments under capital leases	-36K
Repayments on Facility Agreement
Proceeds from Revolving Credit Facility	38M
Repayments on Revolving Credit Facility	-47M
Net cash (used in) provided by financing activities	-8.39M
(Decrease) increase in cash and cash equivalents	-17.9M
Cash and cash equivalents at beginning of period	71.59M
Cash and cash equivalents at end of period	53.69M
Cash paid during the period for interest	724K
Transfer of warrant liability to additional paid-in capital upon exercise of warrants

Entities mentioned with ISTA

View All Entities